公开(公告)号：US08715657B2

公开(公告)日：2014-05-06

申请号：US13265346

申请日：2010-03-29

Applicant: Michael Bardroff ,  Jose M. Carballido Herrera ,  Daniela Della Ducata ,  Christoph Heusser ,  Ute Jaeger ,  Christoph Schwaerzler

Inventor： Michael Bardroff ,  Jose M. Carballido Herrera ,  Daniela Della Ducata ,  Christoph Heusser ,  Ute Jaeger ,  Christoph Schwaerzler

IPC: A61K39/395 ,  C07K16/00 ,  C12P21/08 ,  C12P21/04 ,  C12N15/00 ,  C12N5/02 ,  C07H21/04

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/32

Abstract: The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Abstract translation: 本发明涉及特异性结合IL12R＆lt; 1，异源二聚体IL12受体（连同IL12R＆bgr 2链）的非信号转导链以及IL23受体（连同IL23Rα链）的抗体。 本发明更具体地涉及能够抑制IL12 / IL18诱导的T细胞的IFNγ产生的IL12和IL23受体拮抗剂的特异性抗体，以及用于所述抗体治疗可通过抑制IFNγ产生来治疗的病理学障碍的组合物和方法， 作为类风湿性关节炎，牛皮癣或炎性肠病或其他自身免疫性和炎症性疾病。

公开(公告)号：US09200061B2

公开(公告)日：2015-12-01

申请号：US13302195

申请日：2011-11-22

Applicant: Michael Tesar ,  Ute Jaeger

Inventor： Michael Tesar ,  Ute Jaeger

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C12N9/24 ,  A61K39/00

CPC classification number: C07K16/005 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30 ,  C12N9/2497 ,  C12Y302/02005

Abstract: The present invention provides methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

Abstract translation: 本发明提供了使用重组抗原结合区和抗体的方法以及含有CD38特异性的抗原结合区的功能片段，其在各种病症或病症中起积体作用。 这些方法利用新发现的抗体和这些抗体的令人惊奇的性质，例如结合小型猪来源的CD38的能力和通过交联诱导特异性杀死表达CD38的细胞的能力。 这些抗体以及使用这些抗体的方法可用于治疗例如血液恶性肿瘤例如多发性骨髓瘤。

公开(公告)号：US20150158936A1

公开(公告)日：2015-06-11

申请号：US14309330

申请日：2014-06-19

Applicant: Leslie Ngozi Anuna Johnson ,  Ute Jaeger ,  Yong-In Kim ,  Christian Carsten Silvester KUNZ ,  Igor Splawski ,  Michael Roguska ,  Joy Ghosh ,  Barbara Brannetti ,  Michael Stefanidakis ,  Sha-Mei Liao

Inventor： Leslie Ngozi Anuna Johnson ,  Ute Jaeger ,  Yong-In Kim ,  Christian Carsten Silvester KUNZ ,  Igor Splawski ,  Michael Roguska ,  Joy Ghosh ,  Barbara Brannetti ,  Michael Stefanidakis ,  Sha-Mei Liao

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/24 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863

Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).

Abstract translation: 本发明涉及结合补体因子P并用于其的抗体或其抗原结合片段，以及抗因子P抗体与结合补体成分5（C5）的抗体或其抗原结合片段的组合。

公开(公告)号：US20140248265A1

公开(公告)日：2014-09-04

申请号：US14220166

申请日：2014-03-20

Applicant: Michael Otto BARDROFF ,  Jose M. CARBALLIDO HERRERA ,  Daniela DELLA DUCATA ,  Christoph HEUSSER ,  Ute JAEGER ,  Christoph SCHWAERZLER

Inventor： Michael Otto BARDROFF ,  Jose M. CARBALLIDO HERRERA ,  Daniela DELLA DUCATA ,  Christoph HEUSSER ,  Ute JAEGER ,  Christoph SCHWAERZLER

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/32

Abstract: The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNy production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNy production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Abstract translation: 本发明涉及特异性结合IL12R＆lt; 1，异二聚体IL12受体（连同IL12R＆bgr 2链）的非信号转导链以及IL23受体（连同IL23Rα链）的抗体。 本发明更具体地涉及能够抑制IL12 / IL18诱导的T细胞的IFNγ产生的IL12和IL23受体拮抗剂的特异性抗体，以及用于所述抗体治疗可通过抑制IFNγ产生治疗的病理学障碍的组合物和方法，例如 作为类风湿性关节炎，牛皮癣或炎性肠病或其他自身免疫性和炎症性疾病。

公开(公告)号：US20120034231A1

公开(公告)日：2012-02-09

申请号：US13265346

申请日：2010-03-29

Applicant: Michael Bardroff ,  José M. Carballido Herrera ,  Daniela Della Ducata ,  Christoph Heusser ,  Ute Jaeger ,  Christoph Schwaerzler

Inventor： Michael Bardroff ,  José M. Carballido Herrera ,  Daniela Della Ducata ,  Christoph Heusser ,  Ute Jaeger ,  Christoph Schwaerzler

IPC: A61K39/395 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  A61P29/00 ,  C12N1/19 ,  C12N5/12 ,  C12P21/00 ,  A61P19/02 ,  A61P17/06 ,  C07K16/28 ,  C12N1/15

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/32

Abstract: The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Abstract translation: 本发明涉及特异性结合IL12R＆lt; 1，异源二聚体IL12受体（连同IL12R＆bgr 2链）的非信号转导链以及IL23受体（连同IL23Rα链）的抗体。 本发明更具体地涉及能够抑制IL12 / IL18诱导的T细胞的IFNγ产生的IL12和IL23受体拮抗剂的特异性抗体，以及用于所述抗体治疗可通过抑制IFNγ产生来治疗的病理学障碍的组合物和方法， 作为类风湿性关节炎，牛皮癣或炎性肠病或其他自身免疫性和炎症性疾病。